348 related articles for article (PubMed ID: 24297049)
1. Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma.
Chia WK; Teo M; Wang WW; Lee B; Ang SF; Tai WM; Chee CL; Ng J; Kan R; Lim WT; Tan SH; Ong WS; Cheung YB; Tan EH; Connolly JE; Gottschalk S; Toh HC
Mol Ther; 2014 Jan; 22(1):132-9. PubMed ID: 24297049
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
[TBL] [Abstract][Full Text] [Related]
3. Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.
Comoli P; De Palma R; Siena S; Nocera A; Basso S; Del Galdo F; Schiavo R; Carminati O; Tagliamacco A; Abbate GF; Locatelli F; Maccario R; Pedrazzoli P
Ann Oncol; 2004 Jan; 15(1):113-7. PubMed ID: 14679129
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
Louis CU; Straathof K; Bollard CM; Ennamuri S; Gerken C; Lopez TT; Huls MH; Sheehan A; Wu MF; Liu H; Gee A; Brenner MK; Rooney CM; Heslop HE; Gottschalk S
J Immunother; 2010; 33(9):983-90. PubMed ID: 20948438
[TBL] [Abstract][Full Text] [Related]
5. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.
Smith C; Tsang J; Beagley L; Chua D; Lee V; Li V; Moss DJ; Coman W; Chan KH; Nicholls J; Kwong D; Khanna R
Cancer Res; 2012 Mar; 72(5):1116-25. PubMed ID: 22282657
[TBL] [Abstract][Full Text] [Related]
6. Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.
Comoli P; Pedrazzoli P; Maccario R; Basso S; Carminati O; Labirio M; Schiavo R; Secondino S; Frasson C; Perotti C; Moroni M; Locatelli F; Siena S
J Clin Oncol; 2005 Dec; 23(35):8942-9. PubMed ID: 16204009
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.
Louis CU; Straathof K; Bollard CM; Gerken C; Huls MH; Gresik MV; Wu MF; Weiss HL; Gee AP; Brenner MK; Rooney CM; Heslop HE; Gottschalk S
Blood; 2009 Mar; 113(11):2442-50. PubMed ID: 18971421
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
9. T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results.
Secondino S; Zecca M; Licitra L; Gurrado A; Schiavetto I; Bossi P; Locati L; Schiavo R; Basso S; Baldanti F; Maccario R; Locatelli F; Siena S; Pedrazzoli P; Comoli P
Ann Oncol; 2012 Feb; 23(2):435-41. PubMed ID: 21586688
[TBL] [Abstract][Full Text] [Related]
10. Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients.
Lutzky VP; Davis JE; Crooks P; Corban M; Smith MC; Elliott M; Morrison L; Cross S; Tscharke D; Panizza B; Coman W; Bharadwaj M; Moss DJ
Immunol Cell Biol; 2009; 87(6):481-8. PubMed ID: 19468283
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma.
Lutzky VP; Crooks P; Morrison L; Stevens N; Davis JE; Corban M; Hall D; Panizza B; Coman WB; Coman S; Moss DJ
Clin Vaccine Immunol; 2014 Feb; 21(2):256-9. PubMed ID: 24351754
[TBL] [Abstract][Full Text] [Related]
12. TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma.
Wang G; Mudgal P; Wang L; Shuen TWH; Wu H; Alexander PB; Wang WW; Wan Y; Toh HC; Wang XF; Li QJ
Oncoimmunology; 2021; 10(1):1955545. PubMed ID: 34377592
[TBL] [Abstract][Full Text] [Related]
13. Long-lasting responses with chemotherapy followed by T-cell therapy in recurrent or metastatic EBV-related nasopharyngeal carcinoma.
Secondino S; Pedrazzoli P; Basso S; Bossi P; Bianco A; Imarisio I; Pagani A; De Cicco M; Muscianisi S; Casanova M; Morosi C; Bergamini C; Benazzo M; Cossu Rocca M; Perotti C; Baldanti F; Zecca M; Licitra LF; Comoli P
Front Immunol; 2023; 14():1208475. PubMed ID: 37497213
[TBL] [Abstract][Full Text] [Related]
14. Conserved CTL epitopes within EBV latent membrane protein 2: a potential target for CTL-based tumor therapy.
Lee SP; Tierney RJ; Thomas WA; Brooks JM; Rickinson AB
J Immunol; 1997 Apr; 158(7):3325-34. PubMed ID: 9120290
[TBL] [Abstract][Full Text] [Related]
15. Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.
Chen C; Zhou Y; Zhang X; Fu S; Lin Z; Fang W; Yang Y; Huang Y; Zhao H; Hong S; Zhang L
Cancer Med; 2020 Mar; 9(5):1721-1732. PubMed ID: 31955525
[TBL] [Abstract][Full Text] [Related]
16. Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.
Zheng Y; Parsonage G; Zhuang X; Machado LR; James CH; Salman A; Searle PF; Hui EP; Chan AT; Lee SP
Cancer Immunol Res; 2015 Oct; 3(10):1138-47. PubMed ID: 25711537
[TBL] [Abstract][Full Text] [Related]
17. CTL control of EBV in nasopharyngeal carcinoma (NPC): EBV-specific CTL responses in the blood and tumors of NPC patients and the antigen-processing function of the tumor cells.
Lee SP; Chan AT; Cheung ST; Thomas WA; CroomCarter D; Dawson CW; Tsai CH; Leung SF; Johnson PJ; Huang DP
J Immunol; 2000 Jul; 165(1):573-82. PubMed ID: 10861098
[TBL] [Abstract][Full Text] [Related]
18. Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.
Li J; Chen QY; Mo H; Zhang YL; Huang ZF; Zeng YX
Int J Biol Sci; 2011; 7(5):607-17. PubMed ID: 21614153
[TBL] [Abstract][Full Text] [Related]
19. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.
Straathof KC; Bollard CM; Popat U; Huls MH; Lopez T; Morriss MC; Gresik MV; Gee AP; Russell HV; Brenner MK; Rooney CM; Heslop HE
Blood; 2005 Mar; 105(5):1898-904. PubMed ID: 15542583
[TBL] [Abstract][Full Text] [Related]
20. Expression of immune-related molecules in primary EBV-positive Chinese nasopharyngeal carcinoma: associated with latent membrane protein 1 (LMP1) expression.
Li J; Zhang XS; Xie D; Deng HX; Gao YF; Chen QY; Huang WL; Masucci MG; Zeng YX
Cancer Biol Ther; 2007 Dec; 6(12):1997-2004. PubMed ID: 18087217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
